SCHEMBL1892298

SCHEMBL1892298

O=c1[nH]c2c(oc3ccccc32)c(=O)n1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FEN1 P39748 11/20 1.00
▸ ERCC5 P28715 6/20 1.00
▸ ALDH1A1 P00352 5/20 0.59
▸ KDM4E B2RXH2 3/20 0.59
▸ HTT P42858 1/20 0.59
▸ RXFP1 Q9HBX9 7/20 0.56
▸ PPARG P37231 6/20 0.56
▸ NR2E3 Q9Y5X4 6/20 0.56
▸ NCOR2 Q9Y618 6/20 0.56
▸ NPSR1 Q6W5P4 3/20 0.51
▸ ERCC1 P07992 2/20 0.50
▸ ERCC4 Q92889 2/20 0.50
▸ CA12 O43570 1/20 0.50
▸ RNASEH1 O60930 1/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ LMNA P02545 4/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ GLA P06280 1/20 0.47
▸ GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1889958 0.74 ERCC5 (0.57) FEN1ERCC5ALDH1A1KDM4EHTT
SCHEMBL18774623 0.73 ERCC5 (0.56) FEN1ERCC5ALDH1A1KDM4EHTT
SCHEMBL5323077 0.71 ALDH1A1 (0.56) FEN1ERCC5ALDH1A1KDM4EHTT
SCHEMBL8691721 0.70 ERCC5 (0.54) FEN1ERCC5ALDH1A1KDM4EHTT
SCHEMBL1309845 0.70 ERCC5 (0.54) FEN1ERCC5ALDH1A1KDM4EHTT
SCHEMBL2389722 0.69 ERCC5 (0.52) FEN1ERCC5ALDH1A1KDM4EHTT
SCHEMBL29446409 0.68 RXFP1 (0.61) FEN1ERCC5ALDH1A1KDM4EHTT
SCHEMBL7499024 0.67 ERCC5 (0.50) FEN1ERCC5ALDH1A1KDM4EHTT
SCHEMBL1520708 0.67 FEN1 (1.00) FEN1ERCC5ALDH1A1KDM4EERCC1
SCHEMBL29933774 0.67 FEN1 (1.00) FEN1ERCC5ALDH1A1KDM4EERCC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 — — US claimed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 — — US claimed
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 — — US disclosed
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 — — US disclosed
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 — — US disclosed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 — — US disclosed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 — — US disclosed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 — — US disclosed
WO-2006014647-A2 CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF ATHERSYS, INC. (US) 2006-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof FEN1, UNG, POLH FEN1 1/4885ERCC5 73/4885ALDH1A1 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback